Naimish  Patel net worth and biography

Naimish Patel Biography and Net Worth

Chief Medical Officer of CRISPR Therapeutics

Naimish Patel, M.D., serves as our Chief Medical Officer. He joined CRISPR Therapeutics from Sanofi, where he most recently served as the Global Development Therapeutic Area Head of Immunology and Inflammation. Previously, he was the Global Program Head for Dupilumab at Sanofi, leading multiple waves of indication expansion including chronic obstructive pulmonary disease and eosinophilic esophagitis. During his time at Sanofi, Naimish led the development of an industry leading pipeline across key therapeutic areas including respiratory, dermatology, gastroenterology, and rheumatology. He also oversaw key business development and M&A activities during a rapid phase of pipeline expansion. He is a pulmonary and critical care physician with an extensive background in translational medicine and clinical trials.

Naimish received a B.S. in Mechanical Engineering from MIT and an M.D. from McGill University. He completed his internal medicine training at Columbia-Presbyterian Hospital and his fellowship training in Pulmonary and Critical Medicine at Harvard Medical School. After completing his fellowship, Naimish was a member of the faculty at Harvard and Beth Israel Deaconess Medical Center where he led an NIH-funded lab in translational immunology focused on innate defense functions of the lungs. He previously held positions in clinical development and discovery project leadership at AstraZeneca and Vertex Pharmaceuticals.

What is Naimish Patel's net worth?

The estimated net worth of Naimish Patel is at least $353.04 thousand as of May 29th, 2025. Dr. Patel owns 6,068 shares of CRISPR Therapeutics stock worth more than $353,036 as of December 4th. This net worth approximation does not reflect any other assets that Dr. Patel may own. Learn More about Naimish Patel's net worth.

How do I contact Naimish Patel?

The corporate mailing address for Dr. Patel and other CRISPR Therapeutics executives is BAARERSTRASSE 14, ZUG V8, CH-6300. CRISPR Therapeutics can also be reached via phone at (141) 561-3277 and via email at [email protected]. Learn More on Naimish Patel's contact information.

Has Naimish Patel been buying or selling shares of CRISPR Therapeutics?

Naimish Patel has not been actively trading shares of CRISPR Therapeutics during the last quarter. Most recently, Naimish Patel sold 3,932 shares of the business's stock in a transaction on Thursday, May 29th. The shares were sold at an average price of $35.94, for a transaction totalling $141,316.08. Following the completion of the sale, the insider now directly owns 6,068 shares of the company's stock, valued at $218,083.92. Learn More on Naimish Patel's trading history.

Who are CRISPR Therapeutics' active insiders?

CRISPR Therapeutics' insider roster includes Bradley Bolzon (Director), Julianne Bruno (COO), Kurt Emster (Director), Simeon George (Director), John Greene (Director), Tony Ho (VP), James Kasinger (General Counsel), Lawrence Klein (COO), Samarth Kulkarni (CEO), Rodger Novak (President), Naimish Patel (Chief Medical Officer), Raju Prasad (CFO), and Michael Tomsicek (CFO). Learn More on CRISPR Therapeutics' active insiders.

Are insiders buying or selling shares of CRISPR Therapeutics?

In the last year, CRISPR Therapeutics insiders bought shares 2 times. They purchased a total of 996,812 shares worth more than $51,813,868.36. In the last year, insiders at the sold shares 8 times. They sold a total of 92,526 shares worth more than $5,560,017.15. The most recent insider tranaction occured on October, 17th when CEO Samarth Kulkarni sold 50,895 shares worth more than $3,456,279.45. Insiders at CRISPR Therapeutics own 4.3% of the company. Learn More about insider trades at CRISPR Therapeutics.

Information on this page was last updated on 10/17/2025.

Naimish Patel Insider Trading History at CRISPR Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/29/2025Sell3,932$35.94$141,316.086,068View SEC Filing Icon  
See Full Table

Naimish Patel Buying and Selling Activity at CRISPR Therapeutics

This chart shows Naimish Patel's buying and selling at CRISPR Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

CRISPR Therapeutics Company Overview

CRISPR Therapeutics logo
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
Read More

Today's Range

Now: $58.18
Low: $54.93
High: $59.77

50 Day Range

MA: $61.39
Low: $49.29
High: $76.78

2 Week Range

Now: $58.18
Low: $30.04
High: $78.48

Volume

3,099,579 shs

Average Volume

2,391,821 shs

Market Capitalization

$5.54 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.74